PGHL Q2'27 Sales Up 18% to ₹376 Cr, PAT Jumps 26% to ₹112 Cr
Procter & Gamble Health Ltd. reported Q2 FY27 results with sales up 18% to ₹376 crore and PAT up 26% to ₹112 crore. MD Milind Thatte highlighted strong brand fundamentals and consumer response to innovations.
Significant year-on-year growth in both top-line (sales) and bottom-line (PAT) is a material development for the company and its investors.
The company reported strong double-digit growth in both sales and profit after tax, indicating a positive financial performance and market reception.
Procter & Gamble Health Limited (PGHL) announced its unaudited financial results for the second quarter ended September 30, 2026. The company reported a significant increase in sales, reaching ₹376 crores, an 18% rise compared to the same period last year. This growth was attributed to strong brand performance, effective retail strategies, successful new product innovations, and enhanced go-to-market capabilities.
Profit After Tax (PAT) for the quarter stood at ₹112 crores, marking a substantial 26% increase year-on-year. This improvement in profitability was driven by sales growth and productivity gains across the value chain.
Milind Thatte, Managing Director, P&G Health India, expressed satisfaction with the quarter's performance, highlighting double-digit topline and bottom-line growth. He noted the positive consumer and healthcare professional response to their science-backed products and innovations, particularly in the context of increasing consumer focus on preventive health. Thatte also emphasized the impact of strong retail execution, new communication strategies, HCP awareness initiatives, and strengthened supply chain capabilities.
He further stated that the company is focused on delivering balanced growth and value creation for all stakeholders through a strategy centered on a focused portfolio of trusted brands, superiority in product, package, communication, and retail execution, constructive disruption, productivity, and an agile organization.
What to do with a filing like this
Procter & Gamble Health Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Procter & Gamble Health Limited. Read the original for the full detail.